| Prospective
Clinical Trials Retrospective Studies Members |
Publications Questionnaire Study Administration |
Publications
To see 'CLWP Updates' written for the 'EBMT News' click
here
Crawley C, Szydlo R, Lalancette M, Bacigalupo A, Lange A, Brune M, Juliusson G, Nagler A, Gratwohl A, Passweg J, Komarnicki M, Vitek A, Mayer J, Zander A, Sierra J, Rambaldi A, Ringden O, Niederwieser D, Apperley JF; Chronic Leukemia Working Party of the EBMT. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood. 2005 Nov 1;106(9):2969-76
Martinez MT, Bucher Ch, Stussi G, Heim D, Buser A, Tsakiris DA, Tichelli A, Gratwohl A, Passweg JR. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. Bone Marrow Transplant. 2005 Dec;36(11):993-1000.
J.H. Bourhis, Y. Bouko, S. Koscielny, M. Bakkus, H. Greinix, G. Derigs, G. Salles, W. Feremans, J. Apperley, D. Samson, B. Björkstrand, D. Niederwieser, G. Gahrton, J.L. Pico, H. Goldschmidt. Cell Pro study comparing selected CD34+ versus unselected PBSC. BMT; 2005
Schonland SO, Lokhorst H, Buzyn A, Leblond V, Hegenbart U, Bandini G, Campbell A, Carreras E, Ferrant A, Grommisch L, Jacobs P, Kroger N, La Nasa G, Russell N, Zachee P, Goldschmidt H, Iacobelli S, Niederwieser D, Gahrton G; Chronic Leukemia Working Party; Myeloma Subcommittee of the European Cooperative Group for Blood and Marrow Transplantation. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood. 2006 Mar 15;107(6):2578-84
Gahrton G, Iacobelli S, Apperley J, Bandini G, Bjorkstrand B, Blade J, Boiron JM, Cavo M, Cornelissen J, Corradini P, Kroger N, Ljungman P, Michallet M, Russell NH, Samson D, Schattenberg A, Sirohi B, Verdonck LF, Volin L, Zander A, Niederwieser D. The impact of donor gender on outcome of allogeneic hematopoietic stem cell transplantation for multiple myeloma: reduced relapse risk in female to male transplants. Bone Marrow Transplant. 2005 Mar;35(6):609-17.
Crawley C, Lalancette M, Szydlo R, Gilleece M, Peggs K, Mackinnon S, Juliusson G, Ahlberg L, Nagler A, Shimoni A, Sureda A, Boiron JM, Einsele H, Chopra R, Carella A, Cavenagh J, Gratwohl A, Garban F, Zander A, Bjorkstrand B, Niederwieser D, Gahrton G, Apperley JF. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood. 2005 Jun 1;105(11):4532-9.
Windrum P, Morris TC, Drake MB, Niederwieser D, Ruutu T; EBMT Chronic Leukaemia Working Party Complications Subcommittee. Variation in dimethyl sulfoxide use in stem cell transplantation: a survey of EBMT centres. Bone Marrow Transplant. 2005 Oct;36(7):601-3.
Hertenstein B, Hambach L, Bacigalupo A, Schmitz N, McCann S, Slavin S, Gratwohl A, Ferrant A, Elmaagacli A, Schwertfeger R, Locasciulli A, Zander A, Bornhauser M, Niederwieser D, Ruutu T; Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Development of leukemia in donor cells after allogeneic stem cell transplantation - a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2005 Jul;90(7):969-75.
Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P, Einsele H, Cordonnier C; Acute and Chronic Leukemia Working Parties; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 2005 Nov;36(9):757-69.
Dreger P, Brand R, Milligan D, Corradini P, Finke J, Lambertenghi Deliliers G, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D; Chronic Leukemia Working Party of the EBMT. Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. Leukemia. 2005 Jun;19(6):1029-33.
M. Oosterveld. Intensive treatment strategies in patients with high-risk MDS and sAML, a study towards a risk adapted approach. Thesis. 2005
Ruutu T, Corradini P, Gratwohl A, Holler E, Apperley J, Dini G, Rocha V, Schmitz N, Socie G, Niederwieser D. Use of intrathecal prophylaxis in allogeneic haematopoietic stem cell transplantation for malignant blood diseases: a survey of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2005 Jan;35(2):121-4
Kröger N. Stem cell transplantation from identical twins in patients with myelodysplastic syndromes: no increased relapse risk compared to HLA-identical sibling transplantation. Bone Marrow Transplant. 2005 Jan;35(1):37-43
Morris C. Benefit and timing of second transplants in multiple myeloma; clinical findings and methodological limitations in an EBMT registry study. J Clin Oncol. 2004; 22(9): 1674-1681
Tiercy JM. Isolated HLA-C mismatches in unrelated donor transplantation for CML. BMT. 2004; 34(3):249-55
Lange T. BCR-ABL transcripts are early predictors for hematological relapse in CML after hematopoietic cell transplantation (HCT) with reduced intensity conditioning. Leukemia. 2004;18(9):1468-75
Bakkus MHC. Post-transplantation tumour load in bone marrow, as assessed by quantitative ASO-PCR, is a prognostic parameter in multiple myeloma. British Journal of Haematology. 2004; Volume 126, Issue 5, Page 665-674
Niederwieser D. Transmission of donor illness by stem cell transplantation: should screening be different in older donors? BMT 2004 Oct;34(8):657-65
Fang Y;Gratwohl A;van Houwelingen HC. Relapse risk assessment of transplantation for patients with chronic myeloid leukaemia. Chin Med J (Engl) 2003; 116:305-308
Dreger P, Brand R, Hansz J, Milligan D, Corradini P, Finke J, Deliliers GL, Martino R, Russell N, van Biezen A, Michallet M, Niederwieser D. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-848
Einsele H, Bertz H, Beyer J, Kiehl MG, Runde V, Kolb HJ, Holler E, Beck R, Schwertfeger R, Schumacher U, Hebart H, Martin H, Kienast J, Ullmann AJ, Maschmeyer G, Krüger U, Niederwieser D, Link H, Schmidt CA, Oettle H, Klingebiel T. Infectious complications after allogeneic stem cell transplantation - epidemiology and interventional therapy strategies - guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2003; 82(Suppl. 2): 175-85
Olavarria E, Ottmann OG, Deininger M, Clark RE, Bandini G, Byrne J, Lipton J, Vitek A, Michallet M, Siegert W, Ullmann A, Wassmann B, Niederwieser D, Fischer T (for Chronic Leukemia Working Party of the European Group for Bone and Marrow Transplantation (EBMT). Response to imatinib in patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Leukemia 2003; 17(9): 1707-12
Gahrton G, Apperley J, Bacigalupo A, Björkstrand B, Blade J, Cavo M, Cornelissen J, Corradini C, Crawley C, de Laurenzi A, Facon T, Ljungman P, Michallet M, Niederwieser D, Powles R, Reiffers J, Russel NH, Samson D, Schattenberg AV, Tura S, Verdonck LF, Vernant JP, Willemze R, Volin L. Allogeneic transplantation in multiple myeloma - the EBMT experience. Haematologica 2003; 88:22-23
Oosterveld M;Suciu S;Verhoef G;Labar B;Belhabri A;Aul C;Selleslag D;Ferrant A;Wijermans P;Mandelli F;Amadori S;Jehn U;Muus P;Zittoun R;Hess U;Anak O;Beeldens F;Willemze R;de Witte T. The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921). Leukemia. 2003; 17:859-868
Dreger P;Brand R;Hansz J;Milligan D;Corradini P;Finke J;Deliliers GL;Martino R;Russell N;Van Biezen A;Michallet M;Niederwieser D. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia. 2003; 17:841-848
Cwynarski K;Roberts IA;Iacobelli S;Van Biezen A;Brand R;Devergie A;Vossen JM;Aljurf M;Arcese W;Locatelli F;Dini G;Niethammer D;Niederwieser D;Apperley JF. Stem cell transplantation for chronic myeloid leukemia in children. Blood. 2003; 102:1224-1231
Corradini P, Cavo M, Lokhorst H, Martinelli G, Terragna C, Majolino I, Valagussa P, Boccadoro M, Samson D, Bacigalupo A, Russell N, Montefusco V, Voena C, Gahrton G. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood. 2003; 102:1927-1929
A Gratwohl, H Baldomero, J Passweg, F Frassoni, D Niederwieser, N Schmitz and A Urbano-Ispizua for the Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) in cooperation with the Working Parties Acute (ALWP) and Chronic Leukemias (CLWP) and the Lymphoma Working Party. Hematopoietic stem cell transplantation for hematological malignancies in Europe. Leukemia. 2003; 17: 941 – 959
Ljungman P, Brand R, Einsele H, Frassoni F, Niederwieser D, Cordonnier C. Donor CMV serological status and outcome of CMV seropositive recipients after unrelated donor stem cell transplantation; an EBMT Megafile analysis. Blood. 2003 Aug 21 epub
Oosterveld M, Muus P, Suciu S, Koller C, Verhoef G, Labar B, Wijermans P, Aul C, Fiere D, Selleslag D, Willemze R, Gratwohl A, Ferrant A, Mandelli F, Cortes J, de Witte T, Estey E. Chemotherapy only compared to chemotherapy followed by transplantation in high risk myelodysplastic syndrome and secondary acute myeloid leukemia; two parallel studies adjusted for various prognostic factors. Leukemia. 2002; 16:1615-1621.
Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A, Niederwieser D, Zander AR, de Witte T. Allogeneic stem cell transplantation for adult CMML: a report on behalf of the CLWP of the EBMT. British Journal of Hematology, 2002, 118, 67-73.
Olavarria E, Reiffers J, Boque C, Sureda A, Meloni G, Michallet M, Clark R, Blaise D, Carella A, Cahn JY, Jouet JP, Rizzoli V, Van Biezen A, Gratwohl A, Goldman JM, Niederwieser D, Apperley JF. The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for CML in chronic phase. British Journal of Hematology, 2002, 118, 762-770.
Ruutu T, Hermans J, Niederwieser D, Gratwohl A, Kiehl M, Volin L, Bertz H, Ljungman P, Spence D, Verdonck LF, Prentice HG, Bosi A, du Toit CE, Brinch L, Apperley JF. Thrombotic thrombocytopenic purpura after allogeneic stem cell transplantation: a survey of the EBMT. British Journal of Hematology, 2002, 118, 1112-1119.
Gratwohl A; Brand R;Apperley J; Biezen A.A; Bandini G; Devergie A; Schattenberg A; Frassoni F; Guglielmi C; Iacobelli S; Michallet M; Kolb HJ; Ruutu T;Niederwieser D; Graft-versus-host-disease and outcome in HLA-identical sibling transplantations for CML. Blood, 1 December 2002, vol. 100, nº 12, 3877-3886.
Gugliemli C, Arcese W, Dazzi F, Brand R, Bunjes D, Verdonck LF, Schattenberg A, Kolb HJ, Ljungman P, Devergie A, Bacigalupo A, Urbano-Ispizua A, Michallet M, Elmaagacli A, Gratwohl A, Apperley J, Niederwieser D, Donor Lymphocyte Infusion for relapsed CML: prognostic relevance of the initial cell dose. Blood, 15 July 2002, vol. 100, nº. 2, 397-405.
Guardiola P, Runde V, Bacigalupo A, Ruutu T, Locatelli F, Boogaerts M, Pagliuca A, Cornelissen J, Shouten H, Carreras E, Finke J, van Biezen A, Brand R, Niederwieser D, Gluckman E, de Witte T. Retrospective comparison of BM and granulocyte colony-stimulating factor mobilized PB progenitor cells for allogeneic stem cell transplantations using HLA-identical sibling donors in MDS. Blood 15 June 2002, vol. 99, nº. 12, 4370-4378.
Posthuma EFM, Falkenburg JHF, Apperley JF, Gratwohl A, Roosnek E, Hertenstein B, Schipper RF, Schreuder GMT, D'Amaro J, Oudshoorn M, van Biezen JH, Hermans J, Willemze R, Niederwieser D. HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukaemia (CML). Blood 1999, 93: 3863-3865.
Boiron JM, Cahn JY, Meloni G, Carlo-Stella C, Bandini G, Reman O, Milpied N, Apperley JF, Reiffers J for the EBMT Working Party on Chronic Leukaemia. Chronic myeloid leukaemia in first chronic phase not responding to alpha-interferon: outcome and prognostic factors after autologous transplantation. Bone Marrow Transplantation 1999, 24: 259-264.
Gahrton G, Svensson H, Bjorkstrand B, Apperley JF, Carlson K, Cavo M, Ferrant A, Fouillard L, Gratecos N, Gratwohl A, Guilhot F, Lambertenghi G, Milligan DW, Powles RL, Reiffers J, Samson D, Vernant JP, Volin L, Walvik J for the European Group for Blood and Marrow Transplant. Syngeneic transplantation in multiple myeloma - a case matched comparison of autologous and allogeneic transplantation. Bone Marrow Transplantation. 1999, 24: 741-746.
Michallet M, Thiebaut A, Apperley JF. Peripheral blood progenitor cell mobilisation and transplantation after fludarabine therapy in chronic lymphocytic leukaemia. British Journal of Haematology 2000, 108: 595-601.
Guglielmi C, Arcese W, Hermans J, Bacigalupo A, Bandini G, Bunjes D, Carreras E, Devergie A, Frassoni F, Goldman JM, Gratwohl A, Kolb1 HJ, Iori1 AP, Niederwieser D, Prentice HG, de Witte T, Apperley JF. Risk assessment in patients with Ph+ chronic myelogenous leukemia at first relapse after allogeneic stem cell transplant. An EBMT retrospective analysis. Blood. 2000, 95: 3328-34.
Posthuma EFM, Falkenburg JHF, Apperley JF, Grat-wohl A, Herten-stein B, Schipper RF, GMT Schreuder GMT, D'Ama-ro J, Ouds-hoorn M, van Bie-zen A, Her-mans J, Willem-ze R, Roosnek E, Nie-der-wie-ser D. on behalf of the Chro-nic Leukemia Wor-king Par-ty of the European Blood and Marrow Trans-plant Registry. HLA-DR4 is associated with a diminsihed risk of the development of chronic myeloid leukaemia (CML). Leukemia 2000, 14: 859-862.
de Witte T, Hermans J, Vossen J, Bacigalupo A, Meloni G, Jacobsen N,
Ruutu T, Ljungman P, Gratwohl A, Runde V, Niederwieser D, van Biezen A
, Devergie A, Cornelissen J, Jouet JP, Arnold R, Apperley JF. Haematopietic
stem cell transplantation for patients with myelodysplastic syndromes
and secondary acute myeloid leukaemias: a report on behalf of the Chronic
Leukaemia Working Party of the European Group for Blood and Marrow Transplantation.
British Journal of Haematology 2000 110: 620-630.
Gratwohl A, van Biezen A, Hermans J, Apperley JF for the Chronic Leukaemia
Working Party of the European Group for Blood and Marrow Transplantation.
Role of splenic irradaition in patients with chronic myeloid leukaemia
undergoing allogeneic bone marrow transplantation. Biology of Blood
and Marrow Transplantation 2000, 6: 211-212.
Ruutu T, Herman J, van Biezen, Niederweiser D, Gratwohl A, Apperley JF.
How should corticosteroids be used in the treatment of acute GVHD.
Bone Marrow Transplant 1998; 22: 614-615.
Blade J, Samson D, Reece D, Apperley J, Bjorkstrand B, Gahrton G, Gertz M, Giralt S, Jagannath S, Vesole D. on behalf of the Myeloma subcommittee of the EBMT Chronic Leukaemia Working Party and the Myeloma Working Committee of the IBMTR and the ABMTR. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation. Br J Haematol 1998; 102: 1115-1123.
Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Bandini G, Esperou H, Russell J, de la Rubia J, Girolamo G, Cleeren M, Hartmann O, Clausen J, Ruutu T, Leblond V, Iriondo A, Bosi A, Ben Bassat I, Koza V, Gratwohl A, Apperley JF on behalf of the EBMT Chronic Leukaemia Working Party. Incidence, clinical course and outcome of hepatic veno-occlusive disease VOD after bone marrow transplantation BMT: a prospective cohort study of the European Group for Blood and Marrow Transplantation EBMT. Blood 1998; 92: 3599-3604.
Gratwohl A, Hermans J, Apperley. Risk assessment for bone marrow transplantation in chronic myeloid leukaemia. Lancet 1998; 352: 1087-1092.
Schmitz N, Bacigalupo A, Hasenclever D, Nagler A, Gluckman E, Clark P, Varet B, Greinix H, Frickhofen N, Ringden O, Zander A, Apperley JF, Gorin NC, Borkett K, Schwab G, Goebel M, Russell NH, Gratwohl A. Allogeneic bone marrow transplantation versus filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukaemia: results of a randomised multicentre trial. Bone Marrow Transplant 1998; 21: 995-1003.
Arnold R, de Witte T, van Biezen A, Hermans J, Jacobsen N, Runde V, Vossen J, Willemze R, Samson D, Gratwohl A, Apperley JF. Unrelated bone marrow donor transplantation in patients with myelodysplasia or secondary AML: an EBMT survey. Bone Marrow Transplant 1998; 21: 1213-1216.
Runde V, de Witte T, Arnold R, Gratwohl A, Hermans J, van Biezen A, Niederwieser D, Labopin M, Walter-Noel MP, Bacigalupo A, Jacobsen N, Gahrton G, Carrereas E, Kolb HJ, Aul C, Apperley JF. Bone marrow transplantation from HLA-identical siblings as first line treatment in patients with myelodysplastic syndromes or secondary acute myelogenous leukaemia; a European survey. Bone Marrow Transplant 1998; 21: 255-262.
van Rhee F, Savage D, Blackwell, Orchard K, Dazzi F, Feng Lin, Chase A, Bungey J, Apperley JF, Cross R, Szydlo R, Goldman JM. Adoptive immunotherapy for relapse of chronic myeloid leukaemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched marrow donors. Bone Marrow Transplant 1997; 20: 1055-1062.
de Witte T, van Biezen A, Hermans J, Labopin M, Runde V, Oberg G, Or R, Meloni G, Brunet Mauri S, Bacigalupo A, Apperley JF, Gratwohl A, Gorin NC. Autologous bone marrow transplantation for patients with myelodysplastic syndromes MDS or acute myeloid leukaemia following MDS sAML: a report from the Chronic and Acute Leukaemia Working Parties of the European Bone Marrow Transplant group EBMT. Blood 1997; 90: 3853-3858.
van Rhee F, Szydlo RM, Hermans J, Niederweiser D, Jacobsen N, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Bacigalupo A, de Witte T, Kolb HJ, Link H, Michallet M, Fibbe WE, Ruutu T, Devergie A, Iriondo A, Reiffers J, Nielson J, Goldman JM, Apperley JF, Gratwohl A, for the EBMT Chronic Leukaemia Working Party. Long term results after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant 1997; 20: 553-560.
Devergie A, Apperley JF, Labopin M, Madrigal A, Jacobsen N, Carreras E, Prentice HG, Jouet JP, Kolb HJ, Hertenstein B, Bacigalupo A, Evenson SA, Ljungman P, de Witte T, Reiffers J, Nagler A, Clark RE, Goldman JM, Gratwohl A. European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia: impact of HLA D class II matching. Bone Marrow Transplant 1997; 20: 11-20.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF, on behalf of the EBMT Chronic Leukaemia Working Party. A survey on the prophylaxis and treatment of acute graft versus host disease in Europe. Bone Marrow Transplant 1997; 19: 759-764.
Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley JF, Blade J, Carlson K, Cavo M, Ferrant A, Goldstone AH, de Laurenzi A, Majolino I, Marcus R, Prentice HG Remes K, Samson D, Sureda A, Verdonck LF Volin L, Gahrton G. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case matched study from the European Group for Blood and Marrow Transplantation. Blood 1997; 88: 4711-4718.
Gratwohl A, Hermans J, van Biezen A, Arcese W, de Witte T, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Iriondo A, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schmitz N, Siegert W, Torres-Gomez A, Vernant JP, Zwaan F, Apperley JF, for the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. Br J Haematol 1996; 95: 494-500.
Samson D, Volin L, Burger J, Bosi A, Gahrton G. Interferon maintenance therapy after allogeneic BMT for multiple myeloma: a pilot study of the EBMT. Bone Marrow Transplant 1996; 17: 759-762.
Michallet M, Archimbaud E, Bandini G, et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukaemia CLL. A collaborative study of the EBMT and the IBMTR. Ann Int Med 1996; 124: 311-315.
Gratwohl A, Hermans J, for the Working Party Chronic Leukemia of the European Group for Blood and Marrow Transplantation. Allogeneic bone marrow transplantation for chronic myeloid leukemia. Bone Marrow Transplant 1996; 17 (Suppl. 3): S7-S9.
Békássy AN, Hermans J, Gorin NC, Gratwohl A, for the Acute and Chronic Leukemia Working Parties of the European Group for Blood and Marrow Transplantation. Granulocyte sarcoma after allogeneic bone marrow transplantation: a retrospective European multicenter survey. Bone Marrow Transplant 1996; 17: 801-808.
Kolb HJ, Schattenberg A, Goldman JM. Graft versus leukaemia: effects of donor lymphocytes in marrow grafted patients. Blood 1995; 86: 2041-2050.
Gahrton G, Tura S, Ljungman P. Prognostic factors in autologous bone marrow transplantation for multiple myeloma. J Clini Oncol 1995; 13: 1312-1322.
Gratwohl A, Hermans J, Apperley J, et al. Acute graft-versus-host-disease: grade and outcome in patients with chronic myeloid leukaemia. Blood 1995; 86: 791-796.
Björkstrand B, Goldstone AH, Ljungman P. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT registry study. Leukemia and Lymphoma 1994; 15: 265-272.
Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A, on behalf of the Chronic Leukemia Working Party of the EBMT. Autologous stem cell transplantation in chronic myelogenous leukemia: a retrospective analysis of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 14: 407-410.
Gratwohl A, and J, Hermans. Bone marrow transplantation activity in Europe 1992: Report from the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 1994; 13: 5-10.
Gratwohl A, Hermanns J, Niederwieser D, Frassoni F, Arcese W, Gahrton G, Bandini G, Carreras E, Vernant JP, Bosi A, de Witte T, Fibbe WE Zwaan F, Michallet M, Ruutu T, Devergie A, Iriondo A, Apperley J, Reiffers J, Speck B, Goldman J, for the Chronic Leukemia Working Party of the EBMT. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Bone Marrow Transplant 1993; 12: 509-516.
Arcese W, Goldman JM D,'Arcangelo E, Schattenberg A, Nardi A, Apperley JF, Frassoni F, Aversa F, Prentice HG Ljungman P, Ferrant A, Marosi C, Sayer H, Niederwieser D, Arnold R, Bandini G, Carreras E, Parker A, Frappaz D, Mandelli F, Gratwohl A, for the Chronic Leukemia Working Party of the EBMT. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood 1993; 82: 3211-3219.
Niederwieser W, Arcese W, Bandini G, Schwaighofer H, Thaler J, Bosi A, Di Bartolomeo P, Alessandrino EP Urban C, Gratwohl A, for the Chronic Leukemia Working Party of the EBMT. Prophylactic use of interferon alfa after bone marrow transplantation for patients with chronic myelogenous leukemia at high risk of relapse: a pilot study. Sem. Hematol 1993; 30 (Suppl. 2).
Gratwohl A, Hermans J, v. Biezen A, Arcese W, de Witte T, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Iriondo A, Kolb HJ, Link H, Niederwieser D, Ruutu T, Schmitz N, Siegert W, Torres-Gomez A, Vernant JP, Zwaan FE. Splenic irradiation before bone marrow transplantation for chronic myeloid leukemia: Update of a prospective randomised study. Leukemia & Lymphoma 1993; 11 (Suppl. 1): 227-231.
Ljungman P, De Witte Th. Verdonck L, Gahrton G, Freycon F, Gravett P, McCann S, Morgenstern HG Nikoskelainen J, Powles R, Proctor SJ. Bone marrow transplantation for acute myeloblastic leukaemia: an EBMT Leukaemia Working Party prospective analysis from HLA-typing. Br J Haematol 1993; 84: 61-66.
Gratwohl A, Hermans J, Goldman JM Gahrton G, for the European Group for Bone Marrow Transplantation EBMT. Bone marrow transplantation in Europe: major geographical differences. J Intern Med 1993; 233: 333-341.
Gratwohl A, Hermans J, for the European Group of Bone Marrow Transplantation. Frequency and indication of unrelated bone marrow transplants in Europe. Bone Marrow Transplant 1993; 11 (Suppl. 1): 62-65.
Gratwohl A, Hermans J, v. Biezen A, Arcese W, de Witte T, Debusscher L, Ernst P, Ferrant A, Frassoni F, Gahrton G, Iriondo A, Kolb HJ, Niederwieser D, Ruutu T, Schmitz N, Siegert W, Torres-Gomez A, Vernant JP, Zwaan FE. No advantage for patients who receive splenic irradiation before bone marrow transplantation for chronic myeloid leukemia: results of a prospective randomized study. Bone Marrow Transplant 1992; 10: 147-152.
Gratwohl A, Ljungman P, de Witte T, Verdonck L, Freycon F, Gravett P, McCann S, Morgenstern HG Nikoskelainen J, Powles R, Proctor S, Volin L, Gahrton G, Hermans J, Zwaan F, for the EBMT Leukemia Working Party. In: Mandelli F, ed. Normal and Malignant Hemopoiesis Proceedings of the 5th International Symposium on Therapy of Acute Leukemias Rom 1.-6.11.1991 Leukemia 1992; 6 Suppl. 2 110-113.
Niederwieser D, Grañena A, Hermans J, Kolb HJ, Zwaan FE Gratwohl A, for the Leukaemia Working Party of the European Group of Bone Marrow Transplantation. Slow response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukaemia. Bone Marrow Transplant 1992; 9: 439-443.
November
2004 